Adding Linezolid to Standard Antibiotics for Adults With Staphylococcus Aureus Bloodstream Infection A Randomized Controlled Study

What this Trial Is About

Staphylococcus aureus bloodstream infections are serious and deadly, with high mortality and complications despite available antibiotics. Researchers are evaluating whether adding linezolid, an antibiotic known to inhibit bacterial toxins, to standard treatment can improve outcomes in these infections. This randomized controlled trial aims to test if targeting bacterial virulence factors with linezolid benefits patients with S. aureus bacteraemia. Participants receive either linezolid 600 mg tablets twice daily for 5 days or matching placebo tablets, both alongside standard antibiotic treatment. This is a placebo-controlled, randomized trial designed to assess the additional effect of linezolid when combined with usual care. The treatment period is five days, followed by observation until day 90 to evaluate outcomes. During the study, participants are monitored from the day of randomization through day 90 for clinical outcomes using a Desirability of Outcome Ranking DOOR measure. Researchers collect data on mortality, function, microbiological results, hospital stay, antibiotic use, and safety events, including adverse reactions and laboratory assessments. The study involves detailed follow-up visits and assessments focusing on both efficacy and safety over a three-month period.

Linezolid Plus Standard of Care